Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers

• DOI: 10.3389/fmolb.2024.1385238
• Publication Date: 2024-05-06T09:04:34Z
• Authors: Deepankar Mondal; Sapnita Shinde; Vibha Sinha; Vineeta Dixit; Souvik Paul; Rakesh Kumar Gupta; Suresh Thakur; Naveen Kumar Vish...; Dhananjay Shukla
• Keywords: 0303 health sciences; 03 medical and health sciences; liquid biopsy; QH301-705.5; colorectal cancer; Molecular Biosciences; prognosis; circulating tumor cells; Biology (General); clinical applications; gastrointestinal cancers

Gastrointestinal (GI) cancers account for one-fourth of the global cancer incidence and are incriminated to cause one-third of cancer-related deaths. GI cancer includes esophageal, gastric, liver, pancreatic, and colorectal cancers, mostly diagnosed at advanced stages due to a lack of accurate markers for early stages. The invasiveness of diagnostic methods like colonoscopy for solid biopsy reduces patient compliance as it cannot be frequently used to screen patients. Therefore, minimally invasive approaches like liquid biopsy may be explored for screening and early identification of gastrointestinal cancers. Liquid biopsy involves the qualitative and quantitative determination of certain cancer-specific biomarkers in body fluids such as blood, serum, saliva, and urine to predict disease progression, therapeutic tolerance, toxicities, and recurrence by evaluating minimal residual disease and its correlation with other clinical features. In this review, we deliberate upon various tumor-specific cellular and molecular entities such as circulating tumor cells (CTCs), tumor-educated platelets (TEPs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), exosomes, and exosome-derived biomolecules and cite recent advances pertaining to their use in predicting disease progression, therapy response, or risk of relapse. We also discuss the technical challenges associated with translating liquid biopsy into clinical settings for various clinical applications in gastrointestinal cancers.